Glecaprevir/Pibrentasvir safety in real-world use
Part of Digestive system, Infections clinical trials.
This study watches how safe and well-tolerated the 8-week treatment with glecaprevir/pibrentasvir is for people with hepatitis C who are taking other prescription or illicit drugs. It helps doctors learn more about using this medicine in everyday life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hepatitis C and have not taken any treatment for your current infection.
- Your doctor plans to treat you with 8 weeks of a medicine called glecaprevir/pibrentasvir.
- You are currently taking at least one prescription drug or illegal drug.
- You do not have severe liver failure (decompensated cirrhosis).
- You do not have hepatitis B or liver cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called glecaprevir/pibrentasvir for pregnant women with hepatitis C, with or without HIV. It aims to see how the medicine works in the body and if it is safe during pregnancy.
This trial looks at how two hepatitis C treatments (GLE/PIB or SOF/VEL) interact with other drugs or recreational substances. It may help doctors understand how to better manage treatment for people taking multiple medications.
This study tests whether treating hepatitis C during pregnancy is feasible and acceptable for pregnant women who have a history of drug use. If you qualify, you may receive treatment that could help protect your health and your baby's health.
This study tests a pill combination (sofosbuvir/velpatasvir) to cure hepatitis C. It aims to make treatment simple and accessible, and you can join even if you've had treatment before (if it failed or you got reinfected).
This trial tests whether a very short 4-week course of two hepatitis C drugs (sofosbuvir and glecaprevir-pibrentasvir) can cure hepatitis C in people with early-stage liver disease. The goal is to see if a shorter treatment works as well as longer ones.
This trial looks at hepatitis C treatment for people whose last antiviral medicines did not fully clear the virus. It may help by testing a study drug approach for people in Pakistan who still have active hepatitis C infection.
Hear when a new Hepatitis C Virus (HCV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.